Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darunavir/Ritonavir and Etravirine in Acute HIV Infection
NCT00855413Phase 4Terminated
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Mar 2009
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of darunavir and etravirine in human immunodeficiency virus infection (HIV), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Number of Participants With Virologic Response at 24 weeks. Started Mar 2009; status: terminated.
02
Drugs
darunaviretravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00855413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00855413.